Home › Non-Hodgkin Lymphoma
Pag-aaral pangklinika para sa Non-Hodgkin Lymphoma na nagre-recruit sa U.S.
127 pag-aaral para sa Non-Hodgkin Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX31 pag-aaral
- New York City, NY31 pag-aaral
- Boston, MA26 pag-aaral
- Nashville, TN21 pag-aaral
- Philadelphia, PA20 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Atlanta, GA18 pag-aaral
- Chicago, IL18 pag-aaral
- Columbus, OH18 pag-aaral
- Milwaukee, WI18 pag-aaral
- Washington, DC18 pag-aaral
- Dallas, TX17 pag-aaral
- Durham, NC16 pag-aaral
- Seattle, WA16 pag-aaral
- Portland, OR15 pag-aaral
- Rochester, MN14 pag-aaral
- Miami, FL14 pag-aaral
- Omaha, NE14 pag-aaral
- Denver, CO14 pag-aaral
- Cleveland, OH13 pag-aaral
- Salt Lake City, UT13 pag-aaral
- Mountain View, CA12 pag-aaral
- St. Louis, MO11 pag-aaral
- Aurora, CO11 pag-aaral
- Los Angeles, CA9 pag-aaral
- Tampa, FL9 pag-aaral
- Jacksonville, FL9 pag-aaral
- Cincinnati, OH9 pag-aaral
- San Francisco, CA9 pag-aaral
- Pittsburgh, PA8 pag-aaral
- San Diego, CA8 pag-aaral
- Baltimore, MD8 pag-aaral
- Ann Arbor, MI8 pag-aaral
- Cedar Rapids, IA8 pag-aaral
- Clifton, NJ7 pag-aaral
- Buffalo, NY7 pag-aaral
- Kansas City, MO7 pag-aaral
- Edison, NJ7 pag-aaral
- Birmingham, AL7 pag-aaral
- Queens, NY7 pag-aaral
Ayos sa estado
- Alabama7 pag-aaral
- Arizona14 pag-aaral
- Arkansas5 pag-aaral
- California42 pag-aaral
- Colorado20 pag-aaral
- Connecticut8 pag-aaral
- Delaware4 pag-aaral
- District of Columbia4 pag-aaral
- Florida32 pag-aaral
- Georgia21 pag-aaral
- Hawaii3 pag-aaral
- Idaho3 pag-aaral
- Illinois20 pag-aaral
- Indiana10 pag-aaral
- Iowa10 pag-aaral
- Kansas9 pag-aaral
- Kentucky5 pag-aaral
- Louisiana6 pag-aaral
- Maine4 pag-aaral
- Maryland21 pag-aaral
- Massachusetts28 pag-aaral
- Michigan13 pag-aaral
- Minnesota19 pag-aaral
- Mississippi3 pag-aaral
- Missouri10 pag-aaral
- Montana3 pag-aaral
- Nebraska15 pag-aaral
- New Jersey13 pag-aaral
- New Mexico4 pag-aaral
- New York40 pag-aaral
- North Carolina24 pag-aaral
- North Dakota3 pag-aaral
- Ohio34 pag-aaral
- Oklahoma3 pag-aaral
- Oregon15 pag-aaral
- Pennsylvania26 pag-aaral
- Rhode Island5 pag-aaral
- South Carolina5 pag-aaral
- South Dakota3 pag-aaral
- Tennessee24 pag-aaral
- Texas48 pag-aaral
- Utah14 pag-aaral
- Virginia13 pag-aaral
- Washington20 pag-aaral
- West Virginia3 pag-aaral
- Wisconsin20 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Nagre-recruitPhase 1
Hanggang edad 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT01853631Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Nagre-recruitPhase 1
Edad 12 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Nagre-recruitPhase 1
Edad 12 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT02917083Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07763210A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07582432T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Nagre-recruitPhase 1/2
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Set 30, 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT05645107NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07052305A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT01676805Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03223610A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07519772Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Nagre-recruitPhase 2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05907759Epco, Zanu, Ritux for R/R FL or MZL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04002947Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05798897Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.